Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CLRB logo CLRB
Upturn stock ratingUpturn stock rating
CLRB logo

Cellectar Biosciences Inc (CLRB)

Upturn stock ratingUpturn stock rating
$4.69
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/28/2025: CLRB (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

4 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $47

1 Year Target Price $47

Analysts Price Target For last 52 week
$47 Target price
52w Low $4.11
Current$4.69
52w High $67.5

Analysis of Past Performance

Type Stock
Historic Profit -53.32%
Avg. Invested days 23
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/28/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 14.97M USD
Price to earnings Ratio -
1Y Target Price 47
Price to earnings Ratio -
1Y Target Price 47
Volume (30-day avg) 4
Beta 0.42
52 Weeks Range 4.11 - 67.50
Updated Date 08/28/2025
52 Weeks Range 4.11 - 67.50
Updated Date 08/28/2025
Dividends yield (FY) -
Basic EPS (TTM) -24.28

Earnings Date

Report Date 2025-08-11
When Before Market
Estimate -0.133
Actual -3.39

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -111.74%
Return on Equity (TTM) -273.88%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 5318892
Price to Sales(TTM) -
Enterprise Value 5318892
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -3.25
Shares Outstanding 3192040
Shares Floating 3007700
Shares Outstanding 3192040
Shares Floating 3007700
Percent Insiders 5.98
Percent Institutions 3.6

ai summary icon Upturn AI SWOT

Cellectar Biosciences Inc

stock logo

Company Overview

overview logo History and Background

Cellectar Biosciences Inc. was founded in 2006 and focuses on the discovery, development, and commercialization of phospholipid drug conjugates (PDCs) for the treatment of cancer.

business area logo Core Business Areas

  • PDC Therapeutics: Development of phospholipid drug conjugates (PDCs) for targeted cancer therapies. Their lead asset is CLR 131.
  • Clinical Development: Conducting clinical trials to evaluate the safety and efficacy of PDC therapies.
  • Intellectual Property: Maintaining and expanding a portfolio of patents related to PDC technology.

leadership logo Leadership and Structure

James Caruso serves as the President and CEO. The company operates with a management team focused on clinical development, research, and business development. The company has a board of directors which oversees the companyu2019s strategy and direction.

Top Products and Market Share

overview logo Key Offerings

  • CLR 131 (Iopofosine I 131): CLR 131 is a phospholipid drug conjugate (PDC) designed to deliver targeted radiation directly to cancer cells. It is in clinical development for hematologic malignancies, including multiple myeloma. There is no direct market share data to provide for a drug that is still in the clinical trial stage. Competitors include established therapies for multiple myeloma and other hematologic cancers. Major companies like GSK, Bristol Myers Squibb, Johnson & Johnson, and Amgen develop competing treatments.

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry, specifically oncology, is characterized by intense competition, high regulatory hurdles, and significant research and development investments. Targeted therapies like PDCs are gaining prominence due to their potential for improved efficacy and reduced side effects compared to traditional chemotherapy.

Positioning

Cellectar Biosciences is positioned as a developer of targeted cancer therapies using its PDC platform. Its competitive advantage lies in the potential of PDC technology to selectively deliver therapeutic payloads to cancer cells, improving treatment outcomes.

Total Addressable Market (TAM)

The total addressable market for multiple myeloma treatment is projected to reach billions of dollars annually. Cellectar, if successful, could capture a portion of this market with CLR 131. The TAM for relapsed/refractory multiple myeloma alone is significant.

Upturn SWOT Analysis

Strengths

  • Novel PDC platform for targeted drug delivery
  • Clinical-stage asset (CLR 131) with promising early data
  • Experienced management team
  • Strong IP Portfolio

Weaknesses

  • Limited financial resources
  • Dependence on a single lead asset (CLR 131)
  • High risk associated with clinical development
  • Limited commercial infrastructure

Opportunities

  • Potential to partner with larger pharmaceutical companies
  • Expansion of PDC platform to other cancer types
  • Positive clinical trial results leading to regulatory approval
  • Orphan drug designation and accelerated approval pathways

Threats

  • Clinical trial failures
  • Competition from established therapies and other emerging technologies
  • Regulatory hurdles and delays
  • Difficulty in securing funding

Competitors and Market Share

competitor logo Key Competitors

  • BMY
  • GSK
  • JNJ
  • AMGN

Competitive Landscape

Cellectar's PDC platform offers a unique approach to targeted cancer therapy. However, it faces intense competition from established pharmaceutical companies with marketed therapies and other emerging biotechnology companies developing novel cancer treatments. Its success hinges on demonstrating superior efficacy and safety compared to existing options.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been limited due to the company being in the clinical development stage.

Future Projections: Future growth depends on the successful development and commercialization of CLR 131. Analyst estimates vary widely due to the inherent risks associated with biotechnology companies. Positive clinical trial data will dramatically increase the projected growth.

Recent Initiatives: Recent initiatives include advancing CLR 131 through clinical trials, seeking strategic partnerships, and exploring new applications for the PDC platform.

Summary

Cellectar Biosciences is a clinical-stage biopharmaceutical company with a promising PDC technology. The company's success relies heavily on the successful clinical development of CLR 131. The company faces substantial risks, including clinical trial failures and competition from larger pharmaceutical companies. However, positive clinical results and strategic partnerships could drive significant growth. The company has a novel approach and a strong IP, but is still high risk and has limited financial resources.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company SEC Filings
  • Company Website
  • Analyst Reports
  • Industry Publications

Disclaimers:

This analysis is based on publicly available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Cellectar Biosciences Inc

Exchange NASDAQ
Headquaters Florham Park, NJ, United States
IPO Launch date 2005-11-10
President, CEO & Director Mr. James V. Caruso
Sector Healthcare
Industry Biotechnology
Full time employees 11
Full time employees 11

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. It also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChem Bio. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.